You just read:

Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting

News provided by

Syndax Pharmaceuticals, Inc.

Apr 01, 2019, 10:33 ET